Reneo Pharmaceuticals, Inc.

As of June 30, 2024, Reneo Pharmaceuticals, Inc. has 33.42M shares outstanding.

These figures are as of June 30, 2024.

As of June 30, 2024, Reneo Pharmaceuticals, Inc. maintains a current ratio of 57.86, meaning it holds 57.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2024. Return on assets (ROA) is negative at -49.87, reflecting losses generated across the asset base.

These figures cover the twelve months ended June 30, 2024. Free cash flow yield is negative at -13.09: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.80, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Reneo Pharmaceuticals, Inc. shareholders.

Reneo Pharmaceuticals, Inc.'s most recent stock split took place on October 7, 2024 with a 10:1 split ratio.

As of June 30, 2024, Reneo Pharmaceuticals, Inc. has an Altman Z-Score of 158.93, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.